Research ArticleNeuroscience Free access | 10.1172/jci.insight.128561
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Katsuno, T. in: JCI | PubMed | Google Scholar |
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Belyantseva, I. in: JCI | PubMed | Google Scholar
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Cartagena-Rivera, A. in: JCI | PubMed | Google Scholar |
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Ohta, K. in: JCI | PubMed | Google Scholar |
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Crump, S. in: JCI | PubMed | Google Scholar
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Petralia, R. in: JCI | PubMed | Google Scholar
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Ono, K. in: JCI | PubMed | Google Scholar |
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Tona, R. in: JCI | PubMed | Google Scholar |
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Imtiaz, A. in: JCI | PubMed | Google Scholar
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Rehman, A. in: JCI | PubMed | Google Scholar
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Kiyonari, H. in: JCI | PubMed | Google Scholar |
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Kaneko, M. in: JCI | PubMed | Google Scholar
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Wang, Y. in: JCI | PubMed | Google Scholar
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Abe, T. in: JCI | PubMed | Google Scholar
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Ikeya, M. in: JCI | PubMed | Google Scholar |
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Fenollar-Ferrer, C. in: JCI | PubMed | Google Scholar |
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Riordan, G. in: JCI | PubMed | Google Scholar
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Wilson, E. in: JCI | PubMed | Google Scholar
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Fitzgerald, T. in: JCI | PubMed | Google Scholar |
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Segawa, K. in: JCI | PubMed | Google Scholar |
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Omori, K. in: JCI | PubMed | Google Scholar
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Ito, J. in: JCI | PubMed | Google Scholar
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Frolenkov, G. in: JCI | PubMed | Google Scholar
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Friedman, T. in: JCI | PubMed | Google Scholar
1Department of Otolaryngology-Head and Neck Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
2Laboratory of Molecular Genetics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
3Section on Auditory Mechanics, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
4Advanced Imaging Research Center, Kurume University School of Medicine, Kurume, Japan.
5Department of Physiology, University of Kentucky, Lexington, Kentucky, USA.
6Advanced Imaging Core, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
7Laboratory for Animal Resources and Genetic Engineering, Riken Center for Biosystems Dynamics Research, Kobe, Japan.
8Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
9Laboratory of Molecular and Cellular Neurobiology, National Institute of Mental Health, NIH, Bethesda, Maryland, USA.
10Mouse Auditory Testing Core Facility, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Maryland, USA.
11Department of Otorhinolaryngology, Shinshu University School of Medicine, Matsumoto, Japan.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
Authorship note: TK and IAB contributed equally to this work.
Find articles by Kitajiri, S. in: JCI | PubMed | Google Scholar |
Authorship note: TK and IAB contributed equally to this work.
Published June 20, 2019 - More info
TRIOBP remodels the cytoskeleton by forming unusually dense F-actin bundles and is implicated in human cancer, schizophrenia, and deafness. Mutations ablating human and mouse TRIOBP-4 and TRIOBP-5 isoforms are associated with profound deafness, as inner ear mechanosensory hair cells degenerate after stereocilia rootlets fail to develop. However, the mechanisms regulating formation of stereocilia rootlets by each TRIOBP isoform remain unknown. Using 3 new Triobp mouse models, we report that TRIOBP-5 is essential for thickening bundles of F-actin in rootlets, establishing their mature dimensions and for stiffening supporting cells of the auditory sensory epithelium. The coiled-coil domains of this isoform are required for reinforcement and maintenance of stereocilia rootlets. A loss of TRIOBP-5 in mouse results in dysmorphic rootlets that are abnormally thin in the cuticular plate but have increased widths and lengths within stereocilia cores, and causes progressive deafness recapitulating the human phenotype. Our study extends the current understanding of TRIOBP isoform–specific functions necessary for life-long hearing, with implications for insight into other TRIOBPopathies.
Variants of the human TRIOBP gene have been implicated in the pathogenesis of multiple sclerosis (1), pancreatic cancer (2), and deafness (3–7). TRIOBP encodes 3 protein size classes, TRIOBP-1 (72 kDa, NM_1024716), TRIOBP-4 (107 kDa, NM_001039155), and TRIOBP-5 (218 kDa, NM_1385579) (5, 8) (Figure 1A). TRIOBP was named after its first-characterized isoform, TRIOBP-1, TRIO and F-actin–binding protein-1, also known as TARA. TRIO is a regulator of cytoskeletal remodeling, cell growth, and motility that activates Rho GTPases (9–13). TRIOBP-1 has 5 predicted coiled-coil domains and a pleckstrin homology domain (PH) (Figure 1A), binds and stabilizes actin filaments, and is required for embryonic viability (8, 14–17). TRIOBP-4 is predicted to be a disordered protein that binds F-actin by its R1-repeat motifs (18) and has no amino acid sequence in common with TRIOBP-1, while TRIOBP-5 includes the entire amino acid sequence of TRIOBP-4, most of the sequence of TRIOBP-1, and more (Figure 1A). Thus, TRIOBP-5 contains all of the actin-binding repeat motifs of TRIOBP-4 (18) and additional ones (14). TRIOBP-4 and TRIOBP-5 are expressed in human and mouse retina, brain, and inner ear (5, 6, 8).
Triobp gene structure, transcripts, protein isoforms, and mutant alleles. (A) Alternative transcripts of mouse Triobp, the corresponding encoded protein isoforms, and their predicted domains. Locations of the epitopes for 2 antibodies (TRIOBP-4/5 and TRIOBP-5) are depicted with orange and light-blue rectangles, respectively. (B) Drawing of an organ of Corti sensory epithelium segment showing 1 row of inner (IHC) and 3 rows of outer (OHC) hair cells. Inset shows Deiters’ and outer pillar cells supporting an OHC. (C) Mutations of Triobp used to generate 2 genetically different TRIOBP-5–deficient mouse models. TriobpΔEx9-10/ΔEx9-10 has a LacZ cassette replacing exons 9 and 10 of Triobp-5 (schematic 1). The TriobpΔEx8 allele has a LacZ cassette replacing exon 8 (schematic 2) and the TriobpYHB226 allele has a trap cassette with a LacZ insertion in exon 17 (schematic 3). The combination in trans of these 2 Triobp mutations is a compound heterozygote designated TriobpΔEx8/YHB226. Expression of wild-type Triobp isoforms 1, 4, and 5 is indicated to the right of the schematics for each genotype.
The majority of profound deafness-associated variants of human TRIOBP are located in the large exon 6, orthologous to mouse Triobp exon 8, encoding approximately 2000 residues included in the sequence of TRIOBP-4 and TRIOBP-5 (5, 6, 8) (Figure 1A). Recently, amino acid substitutions in the sequence unique to TRIOBP-5 were found to be associated with moderate hearing loss (4, 7). Additionally, a genome-wide association study (GWAS) identified a noncoding variant of TRIOBP associated with a common form of adult-onset hearing loss (3). These observations underscore the medical importance of understanding TRIOBP isoform-specific functions.
Hearing loss often results from dysfunction of sensory hair cells in the cochlea (19, 20) (Figure 1B). Inner hair cells (IHCs) are the primary sensors of sound-induced vibrations, while outer hair cells (OHCs) are amplifiers of these vibrations (21). Sound stimuli deflect a bundle of stereocilia that project from the apical surface of both IHCs and OHCs and open mechanically gated cation channels, likely TMC1 in a complex with other proteins (22–25). Stereocilia are anchored into the apical surface of the hair cells with their rootlets embedded in the cuticular plate (26–28). In a newborn wild-type (WT) mouse (P0), rootlets are not yet visible, but each stereocilium has already developed a prominent F-actin core. Subsequently, rootlets gradually develop presumably by elongation of central actin filaments of stereocilia cores and thickening to achieve a mature shape by P16 (8, 26, 29, 30), shortly after the onset of hearing (31–33). A mature rootlet has the appearance of a double-pointed needle centrally positioned at the pivot point of a WT stereocilium, extending into its F-actin core about a third to half the length of a stereocilium (referred here as the upper half of a rootlet) and approximately the same distance into the actin meshwork of the cuticular plate (the lower half of a rootlet) (26). Actin filaments within the rootlets are tightly packed with no noticeable space between them, an observation that we recapitulated in vitro using F-actin bundled by purified TRIOBP-4 (8, 18).
We previously engineered a knockout mouse by removing exon 8 of Triobp (TriobpΔEx8/ΔEx8), thus simultaneously ablating TRIOBP-4 and TRIOBP-5 isoforms (Figure 1C), while leaving the expression of TRIOBP-1 intact (8). A TriobpΔEx8/ΔEx8 mouse never develops stereocilia rootlets and is congenitally, profoundly deaf (8). Stereocilia lacking rootlets initially have a normal appearance and are capable of mechanotransduction but are fragile (8). Shortly after the onset of hearing at P16, these floppy stereocilia lacking rootlets fuse together and rapidly degenerate, followed by the death of hair cells (8), presumably the pathogenic process accounting for human profound deafness due to mutations of TRIOBP (5, 6). However, the potential differences in function of TRIOBP-4 and TRIOBP-5 as well as the mechanisms regulating the overall architecture of stereocilia rootlets including their width, length, and shape are unknown.
Here, we determined the specific roles of TRIOBP-4 and TRIOBP-5 in the formation of F-actin bundles of stereocilia rootlets using 2 isoform-specific knockout mouse models, measurements of hair cell mechanical properties using PeakForce Tapping atomic force microscopy and water-jet stimulations, live cell nanoscale pull-down protein-protein interaction assays, as well as 3D reconstructions of rootlets from electron microscopy images. We show that rootlets have 2 separate compartments with different compositions of TRIOBP isoforms. Although TRIOBP-4 alone can initiate rootlet formation, a TRIOBP-5 deficiency results in rootlet dysmorphology and progressive deafness in 2 independent mouse models, mimicking the human phenotype. We also show that WT TRIOBP-5 is essential for the precise dimensions and mechanical resilience of rootlets. Moreover, TRIOBP-5 contributes to the apical stiffness of flanking supporting cells for life-long hearing.
TRIOBP-4 and TRIOBP-5 localize to different rootlet compartments. Immunostaining of WT mouse auditory epithelia with TRIOBP-5–specific antiserum (Figure 1A) revealed TRIOBP-5 localization restricted to the lower half of rootlets, immediately below the apical surface of a hair cell within the cuticular plate (Figure 2A). In contrast, the TRIOBP-4/5 antibody that detects both TRIOBP-4 and TRIOBP-5 isoforms (Figure 1A) stained stereocilia and the entire length of rootlets with a prominent signal present in the F-actin stereocilia core, as previously reported (8) (Figure 2D, inset). This observation indicates that localization of TRIOBP-4 is different from TRIOBP-5. However, an antibody that specifically detects only TRIOBP-4 could not be developed, as TRIOBP-4 and TRIOBP-5 have identical amino-terminal sequences. To circumvent this problem, we developed an R26-EGFP-Triobp-4 transgenic reporter mouse (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.128561DS1). EGFP-TRIOBP-4 was predominantly localized in the upper half of rootlets within stereocilia cores of homozygous R26-EGFP-Triobp-4 reporter mice, while a weak EGFP-TRIOBP-4 signal was observed throughout the hair cell cuticular plate, likely masking a weak EGFP-TRIOBP signal in the lower half of stereocilia rootlets (Figure 2, A and B, and Supplemental Figure 2). The EGFP-TRIOBP-4 signal was very similar to the immunofluorescence detected in the WT using the TRIOBP-4/5 antibody (Figure 2D), demonstrating that the predominant localization of endogenous TRIOBP-4 is in the upper half of rootlets embedded in stereocilia cores (Figure 2, A, B, and D). In contrast, immunostaining of endogenous TRIOBP-5 in the R26-EGFP-Triobp-4 reporter mouse confirmed the restricted localization of TRIOBP-5 in the lower half of a rootlet within the cuticular plate (Figure 2A).
Differential localization of TRIOBP isoforms in stereocilia rootlets revealed in the R26-EGFP-Triobp-4 transgenic reporter mouse. (A) TRIOBP-5–specific antibody signal (red) observed predominantly in the rootlet segment inside the cuticular plate. See single channel images in Supplemental Figure 2. (B) Anti-GFP antibody recognized EGFP-TRIOBP-4 in the stereocilia rootlet segment that resides above the cuticular plate within the stereocilia core (green). A diffuse EGFP signal is present in the cuticular plate (green). (C) In Deiters’ cells located between OHCs, both TRIOBP-4 and TRIOBP-5 are present in F-actin bundles of obliquely ascending processes (arrows). Outer pillar cells show predominantly a TRIOBP-5 signal (red, arrowheads) close to junctions with OHCs. (D) P32 wild-type mouse (C57BL/6J) organ of Corti stained with TRIOBP-4/5 antibody. The inset shows representative IHC, in which TRIOBP-4/5 immunoreactivity (green) is prominent in stereocilia above the cuticular plate and a weaker signal is present in the rootlet segment within the cuticular plate. TRIOBP-4/5 immunoreactivity is also present in stereocilia of OHCs (inset and arrowheads) and in Deiters’ cells (arrows). (E and F) Helios gene gun–mediated transfections of P3 wild-type organ of Corti explants with plasmids expressing either AcGFP1-TRIOBP-5 (E) or AcGFP1-TRIOBP-4 cDNA (F) reveal targeting of AcGFP1-TRIOBP-5 (E) to stereocilia rootlets (green) within the cuticular plate. (F) AcGFP1-TRIOBP-4 predominantly targets the upper half of the rootlets within the stereocilia core, recapitulating the endogenous differential localization of TRIOBP-4 and TRIOBP-5. A barely detectable signal of AcGFP1-TRIOBP-4 was found in the lower half of rootlets within the cuticular plate. F-actin is visualized by blue phalloidin-405 in A–C and rhodamine-phalloidin (red) staining in D–F. All images are maximum intensity projections of confocal Z-stacks or their subsets (inserts). Scale bars: 5 μm (all panels).
A filamentous pattern of EGFP-TRIOBP-4 fluorescence was also detected in the upper portions of the ascending phalangeal processes of Deiters’ supporting cells that flank hair cells (Figure 1B and Figure 2C, arrows). Filamentous structures near the junctions with OHCs in the heads of outer pillar supporting cells (Figure 2C, arrowheads) were also highlighted by TRIOBP-5 antibody staining (Figure 2C, red). Supporting cells are thought to be important for mechanical stiffness of the cochlear partition that shapes sound-induced intracochlear vibrations (34, 35).
Next, AcGFP1-TRIOBP-4 and AcGFP1-TRIOBP-5 were introduced into WT hair cells of P3 mouse organ of Corti explants by biolistic gene-gun transfections (36). We observed isoform-specific targeting of exogenous AcGFP1-TRIOBP-5 (Figure 2E) and AcGFP1-TRIOBP-4 (Figure 2F) to the same subcellular locations that were revealed using antisera and the R26-EGFP-TRIOBP-4 reporter mouse, confirming the differential localization of these isoforms within stereocilia. These data indicate that the upper half of a rootlet within the F-actin core of a stereocilium and its lower half within the cuticular plate have different TRIOBP isoform compositions, even though the entire length of rodent auditory hair cell rootlets appear as a single uniform electron-dense F-actin structure when examined by transmission electron microscopy (TEM) (26).
TRIOBP-5–deficient mice exhibit progressive deafness. The hearing phenotype of mice deficient only for the TRIOBP-5 isoform is unknown. We used 2 different genetic strategies to engineer new mouse models each deficient only for TRIOBP-5. One TRIOBP-5–deficient mouse model was engineered by deleting exons 9 and 10 (TriobpΔEx9-10) unique to TRIOBP-5 and replacing them with a LacZ reporter cassette followed by a translation stop codon (Figure 1C and Supplemental Figure 1). Southern blot analyses confirmed the deletion of exons 9 and 10 (Supplemental Figure 1). RT-PCR detected no Triobp-5–specific mRNA from the inner ear of homozygous mutant mice and no alteration in expression of Triobp-1 and Triobp-4 isoforms (Supplemental Figure 1). Immunostaining with anti–TRIOBP-5 antibody detected no TRIOBP-5 protein in stereocilia rootlets of homozygous Triobp-5ΔEx9-10/ΔEx9-10 mice (Supplemental Figure 1), validating the specificity of this antiserum.
In a TriobpΔEx9-10/+ heterozygous mouse, β-galactosidase activity was detected in spiral ganglion neurons and in the sensory epithelium of the organ of Corti (Supplemental Figure 1). This pattern is similar to the β-galactosidase expression we reported for a heterozygote TriobpΔEx8/+ mouse (8) and indicates that the mRNAs for the Triobp-4 and Triobp-5 isoforms are each expressed in the same inner ear cell types.
A second TRIOBP-5–deficient mouse (TriobpΔEx8/YHB226) was generated by crossing a homozygous TriobpΔEx8/ΔEx8 mouse with a heterozygous TriobpYHB226/+ mouse (Figure 1C). The TriobpYHB226 allele has a gene trap inserted in exon 17, which disrupts expression of TRIOBP-5 and TRIOBP-1. Homozygosity for TriobpYHB226 results in embryonic lethality due to a lack of TRIOBP-1 (8). Compound heterozygous TriobpΔEx8/YHB226 mice express TRIOBP-1 from the TriobpΔEx8 allele, while the TriobpYHB226 allele allows transcription of WT Triobp-4 (Figure 1, A and C). Both TriobpΔEx9-10/ΔEx9-10 mice and TRIOBP-5–deficient compound heterozygous mice were obtained at the expected Mendelian ratio and macroscopically were indistinguishable from their WT littermates. To evaluate the hearing of both TRIOBP-5–deficient mouse models, auditory brainstem responses (ABRs) were recorded (Figure 3). At 4 and 8 weeks of age, TriobpΔEx8/YHB226 mice have residual hearing at 8 and 16 kHz. By 12 weeks of age hearing loss was severe to profound at all frequencies tested (Figure 3A). Four-week-old TriobpΔEx9-10/ΔEx9-10 mice also had residual hearing at 8 and 16 kHz that progressed to severe to profound hearing loss by 8 weeks of age (Figure 3B), indicating a more rapid progression of hearing loss as compared with TriobpΔEx8/YHB226. These deaf mice have no obvious vestibular abnormalities such as circling or head bobbing.
Progressive hearing loss in TRIOBP-5–deficient mice. (A) Average auditory brainstem response (ABR) thresholds in TriobpΔEx8/+ heterozygous control mice (gray/black) and TriobpΔEx8/YHB226 compound heterozygous TRIOBP-5–deficient mice (shades of green). (B) Average ABR thresholds in Triobp+/+ (wild-type) and TriobpΔEx9-10/+ heterozygous controls (gray/black) and in TriobpΔEx9-10/ΔEx9-10 mice (shades of blue). ABRs were measured at 4, 8, and 12 weeks postnatally at frequencies of 8, 16, and 32 kHz. When no response was detected at a maximum stimulus level of 90 dB SPL, the threshold was assigned as 100 dB SPL (dashed line in A and B). Error bars indicate SD. (C) SEM images of P43 mouse IHC and OHC stereocilia bundles from normal-hearing TriobpΔEx8/+ heterozygotes (left) and from deaf TriobpΔEx8/YHB226 (right) compound heterozygotes. (D) SEM images of mouse P35 stereocilia bundles of wild-type and TriobpΔEx9-10/ΔEx9-10 OHCs and IHCs. Note fusion of stereocilia of mutant IHC and loss of stereocilia from longer row in OHC hair bundle. Scale bars: 2 μm in C and right panels in D, and 5 μm in D, left panel.
To evaluate OHC function, we recorded distortion product otoacoustic emissions (DPOAEs) in TriobpΔEx8/YHB226 and TriobpΔEx9-10/ΔEx9-10 mice and their littermate controls. DPOAEs measure cochlear amplification that requires functional OHCs (37). DPOAEs were not detected in TriobpΔEx9-10/ΔEx9-10 or TriobpΔEx8/YHB226 mice by 8 weeks of age. At 4 weeks of age, DPOAEs were absent in 7 of the 16 TriobpΔEx8/YHB226 mice, and the remaining 9 only had low-level DPOAEs within the 8–20 kHz range (Supplemental Figure 3). DPOAEs were absent in 7 TriobpΔEx9-10/ΔEx9-10 mice at 4 weeks of age, with the exception of one mouse with very low DPOAE levels restricted to the 8–11.2 kHz range (Supplemental Figure 3). These data indicate a loss of OHC function in both TRIOBP-5–deficient mouse models, which is consistent with progressive degeneration of hair cells described below.
Degeneration of hair cell stereocilia in mice deficient for TRIOBP-5. Scanning electron microscopy (SEM) revealed a structural explanation for hearing loss in the organs of Corti from TRIOBP-5–deficient mice (TriobpΔEx9-10/ΔEx9-10) and littermate normal hearing controls at P7, P14, P30, and P40. Initially, stereocilia bundles of TRIOBP-5–deficient mice are indistinguishable from controls (Supplemental Figure 4). After P14, hair bundles of TRIOBP-5–deficient mice become disorganized, and many stereocilia of IHCs are fused with one another. By P40, we observed a loss of some stereocilia from OHC hair bundles, predominantly from the longest stereocilia row, perhaps due to their detachment at fragile pivot points near the apical surface of a hair cell (Figure 3D and Supplemental Figure 4). A similar but slower progressive degeneration of the stereocilia bundles was observed in the TriobpΔEx8/YHB226 TRIOBP-5–deficient mouse (Figure 3C and Supplemental Figure 5), consistent with a milder progressive loss of hearing.
TRIOBP-5–deficient mice have dysmorphic rootlets. We hypothesized that in the absence of TRIOBP-5, TRIOBP-4 alone would be capable of forming a rootlet-like structure because F-actin and purified TRIOBP-4 in vitro can form tight actin bundles reminiscent of rootlets (8). To test this hypothesis, ultrastructural analyses were performed on separate TEM images (Figure 4, A–C) and on reconstructions of images of rootlets using both TEM sections (Figure 4, D–F, and Supplemental Figure 6) and consecutive backscattered SEM images after 20-nm-step milling with a focused ion beam (FIB-SEM, Figure 5 and Supplemental Videos 1 and 2). Compared with WT, by P16 hair cells from TriobpΔEx9-10/ΔEx9-10 mice showed a variety of structural defects in the upper half of a rootlet within the stereocilia F-actin core and also in the lower half of a rootlet that is embedded into the cuticular plate (Figure 4 and Supplemental Figure 6). Some stereocilia appeared to be missing the lower half of rootlets, while the other rootlets were thin, fragmented, and dysmorphic in their lower half within the cuticular plate. Sometimes rootlets had interruptions or breaks at sites where a stereocilium inserts into the cuticular plate (Figure 4E). Rootlet abnormalities in TRIOBP-5–deficient mice occurred throughout the length of the cochlea, in all rows of stereocilia (Supplemental Figure 6). Earlier signs of rootlet abnormalities at P7–P9 (Supplemental Figure 7) included an expansion of the upper half of the rootlets within stereocilia cores and loss or thinning of the lower half of some rootlets within cuticular plates, similar to changes reported in cat and chinchilla after noise trauma (38–40).
Structural abnormalities of stereocilia rootlets in TRIOBP-5–deficient mice. (A–C) TEM images of hair cell bundles (P12 and P16) showing representative rootlet morphology and (D–F) 3D reconstructions of stereocilia rootlets from serial TEM sections (P16). wild-type (Triobp+/+) (A and D) and TriobpΔEx9-10/ΔEx9-10 OHCs (B and E), TriobpΔEx9-10/ΔEx9-10 IHC rootlet morphology (C), and 3D reconstruction of wild-type (Triobp+/+) and TriobpΔEx9-10/ΔEx9-10 IHC stereocilia and cuticular plates (F). (C) IHC stereocilium rootlet is dysmorphic, thin, and bent. (E) Arrow points to disrupted rootlet structure at stereocilia pivot points. (G–I) TEM images of the OHC stereocilia in wild-type (Triobp+/+) at P16 (G), and TriobpΔEx8/YHB226 mouse at P14 (H) and P90 (I). Structural defects of rootlets at P14 include splayed bundles of F-actin or bent rootlets (H). Representative structural defects at P90 include fused stereocilia undergoing degeneration (I, left panel) and abnormal asymmetric localization of electron dense material within stereocilia F-actin cores (I, right panel). Scale bars: 500 nm.
FIB-SEM analyses of TriobpΔEx9-10/ΔEx9-10 hair cells show enlargement of rootlets within stereocilia cores and thinning of rootlets within the cuticular plate. (A–P) Reconstruction of stereocilia bundles and stereocilia rootlets from P14 TriobpEx9-10/ΔEx9-10 and TriobpEx9-10/+ IHCs and OHCs. (A, E, I, and M) Sagittal sections showing the morphology of rootlets reconstructed from FIB-SEM data sets. (B, F, J, and N) False-colored 3D reconstructions of hair bundles (blue) and rootlets (yellow and orange) were added to better visualize rootlet structure. (C, G, K, and O) Individual rootlets highlighted in orange show typical morphology for a particular genotype. (D, H, L, and P) Reconstruction of 1 stereocilium (blue) and rootlet selected in C, G, K, and O (orange) from hair cells in B, F, J, and N. The rootlet segments within stereocilia cores of TriobpEx9-10/ΔEx9-10 mice in E–H and M–P are longer and thicker compared with phenotypically wild-type controls in A–D and I–L, while TriobpEx9-10/ΔEx9-10 rootlets within the cuticular plate are abnormally thin. Scale bars: 1 μm. See also Supplemental Videos 1 and 2. (Q) Quantification of the shape of stereocilia and rootlets, rootlet length (red line), and stereocilium length (blue line) and volume of rootlet segment of stereocilia core (yellow) of the tallest row stereocilia of IHCs and OHCs. (R and S) Data in box-and-whisker plots are represented as mean ± SD. Data points represent length of rootlets within the cuticular plate (red) and within the stereocilia cores (blue) of IHCs or OHCs and volume of rootlets within stereocilia cores for Triobp-5ΔEx9-10/+ mice (black; n = 54, 17, 102, 98, 21 and 39) or Triobp-5ΔEx9-10/ΔEx9-10 mice (purple, n = 47, 17, 120, 96, 27, and 34) at P14. ***P < 0.001 compared with control by Mann-Whitney U test. There is a significant difference in rootlet length and rootlet volume in stereocilia cores when comparing Triobp-5ΔEx9-10/+ and Triobp-5ΔEx9-10/ΔEx9-10 mice, while there is no significant difference in stereocilia length.
FIB-SEM images confirmed these morphological findings and allowed for quantification of 3D structures of stereocilia rootlets (Figure 5 and Supplemental Videos 1 and 2). Rootlets of both IHCs and OHCs of P14 TriobpΔEx9-10/ΔEx9-10 mice were hypertrophic within stereocilia cores but abnormally thin, often bent, and elongated within the cuticular plates (Figure 5, A–P). At P7–P14, rootlets of TriobpΔEx9-10/ΔEx9-10 OHCs within stereocilia cores were abnormally expanded, nearly reaching the tips of stereocilia (Figure 5, M–S, and Supplemental Figure 7). We concluded that TRIOBP-5 is required to establish the normal development and intricate architecture of rootlets within stereocilia cores and cuticular plates.
Compared with TriobpΔEx9-10/ΔEx9-10, rootlets in TriobpΔEx8/YHB226 mice were somewhat less affected. While some rootlets were bent, splayed, or had multiple misplaced fragments of rootlet-like dense structures within stereocilia cores, others were of normal thickness and length within the cuticular plate and in the stereocilia core (Figure 4, H and I). Additionally, TriobpΔEx8/YHB226 rootlets degenerated more slowly than rootlets of TriobpΔEx9-10/ΔEx9-10 and persisted even at P90, although dysmorphic (Figure 4I). These observations suggest that the C-terminal portion of TRIOBP-5 contributes to the structural integrity of rootlets, perhaps by fortifying their F-actin bundles to withstand life-long acoustical stimulation.
TRIOBP-4 is present in stereocilia of deaf TRIOBP-5–deficient mice. To examine the localization of TRIOBP-4 in the organ of Corti in the absence of WT TRIOBP-5, we performed immunostaining of TriobpΔEx9-10/ΔEx9-10 and TriobpΔEx8/YHB226 deaf mice. The anti–TRIOBP-5 antibody did not detect TRIOBP-5 in TriobpΔEx9-10/ΔEx9-10 hair cells (Figure 6, A–C, and Supplemental Figure 1), while the TRIOBP-4/5 antibody detected TRIOBP-4 in the cuticular plate and in stereocilia cores of both Triobp-5–deficient mouse models (Figure 6, D and E, and Supplemental Figure 5). However, the anti–TRIOBP-5 antiserum did stain stereocilia rootlets of compound heterozygous TriobpΔEx8/YHB226 mice (Figure 6, F–H). RT-PCR analysis of TriobpΔEx8/YHB226 mouse inner ear mRNA detected Triobp-5 transcripts skipping exons 17 to 23 or 17 to 24 (Supplemental Figure 8). If translated, this transcript could explain the TRIOBP-5 immunoreactivity in the TriobpΔEx8/YHB226 stereocilia rootlets and the less severe deafness of the TriobpΔEx8/YHB226 as compared with the TriobpΔEx9-10/ΔEx9-10 mouse (Figure 3), but cannot substitute for the function of full-length TRIOBP-5 since a TriobpΔEx8/YHB226 mouse eventually becomes profoundly deaf.
Localization of TRIOBP isoforms in P14–P30 TRIOBP-5–deficient mice. (A and B) TRIOBP-5 (green) is localized to the rootlet compartment within the cuticular plate of IHCs (A) and OHCs and in Deiters’ supporting cells (B, white arrows) of normal-hearing TriobpΔEx9-10/+ mice. (C) TRIOBP-5 was not detected in stereocilia rootlets and Deiters’ cells of TriobpΔEx9-10/ΔEx9-10 homozygous TRIOBP-5–deficient mice, confirming antibody specificity. (D) TRIOBP-4/5 antibody detects the TRIOBP-4 isoform in TriobpΔEx9-10/ΔEx9-10 IHC stereocilia rootlet compartment above the cuticular plate. (E) Immunoreactivity to TRIOBP-4/5 antibody is unchanged in Deiters’ cells and OHCs of TriobpΔEx9-10/ΔEx9-10 mice compared to immunoreactivity in phenotypically wild-type heterozygous (TriobpΔEx9-10/+) hair cells (Figure 2B). (F–H) In contrast to the absence of a TRIOBP-5 signal in TriobpΔEx9-10/ΔEx9-10 mice, TRIOBP-5 antibody shows immunoreactivity in compound heterozygous TriobpΔEx8/YHB226 and control TriobpΔEx8/+ mice in the lower portion of stereocilia rootlets in both OHCs and IHCs (arrows in G) and in Deiters’ and outer pillar cells (arrowheads in G and H). Scale bars: 5 μm (all panels).
TRIOBP-5 homo-oligomerizes. Exons 18, 19, 21, 23, and 24 encode residues common to TRIOBP-1 and TRIOBP-5 that are predicted to form 5 coiled-coil domains (Figure 1A and Supplemental Figure 8). Some of these coiled-coils allow TRIOBP-1 to oligomerize (14). To gain additional insight into the domain architecture and possible dimerization of mouse TRIOBP-5, we performed an amino acid sequence analysis to identify putative coiled-coil domains using COILS (41). Five coiled-coil domains were identified at residues 1669–1689, 1719–1754, 1792–1819, 1890–1917, and 1928–1962 of mouse TRIOBP-5 (NCBI ABB59557.2), equivalent to the coiled-coil domains described for human TRIOBP-5 (14). Next, we generated an in silico template-based structural model (see Methods and Supplemental Figure 8) in order to analyze the 3D arrangement of these coiled-coil domains. Similar to that of the template, the resulting model has a dimer architecture containing 2 protein chains of the C-terminal domain of mouse TRIOBP-5 covering residues 1713–1868, which correspond to the predicted coiled-coils 2 and 3 (Figure 1A and Supplemental Figure 8).
To experimentally test predictions of the computational model that TRIOBP-5 can homo-oligomerize, we employed a NanoSPD assay, which utilizes a myosin-10 motor for a nanoscale pull down to detect a protein-protein interaction in live cells (42). The MYO10-HMM-Nanotrap (MYO10NANOTRAP) construct was designed to bind specifically to GFP (it does not bind DsRed) and transport it to the tips of filopodia (42). HeLa cells were transfected simultaneously with 3 expression constructs: MYO10NANOTRAP, AcGFP1-TRIOBP-5, and DsRed-TRIOBP-5. The MYO10NANOTRAP bound AcGFP1-TRIOBP-5 and delivered it to filopodia tips. Yellow fluorescence at the tips indicated that DsRed-TRIOBP-5 interacted with AcGFP1-TRIOBP-5, and this macromolecular complex was shuttled to filopodia tips (Figure 7, A and C, and Supplemental Figure 9). In control experiments, we transfected the MYO10NANOTRAP, DsRed-TRIOBP-5, and AcGFP1 expression vectors and observed only GFP fluorescence at the tips of filopodia, indicating that neither MYO10NANOTRAP nor the AcGFP1 vector were able to interact with DsRed-TRIOBP-5 and traffic it to filopodia tips (Figure 7, A and C). As an additional control, AcGFP1-TRIOBP-5 coexpressed with DsRed-TRIOBP-5, but without MYO10NANOTRAP, colocalized within the cytoplasm, forming punctate structures that were not observed at filopodia tips (Supplemental Figure 9). DsRed-TRIOBP-5 alone was only present in the cytoplasm as punctate structures (Supplemental Figure 9), arguing for the necessity of the active transport of this protein to filopodia tips by the myosin-10 motor in conjunction with bound AcGFP1-TRIOBP-5. To determine if homo-oligomerization of TRIOBP-5 depends on the coiled-coil domains, the sequence encoding the coiled-coil domains was deleted from TRIOBP-5. This internally deleted TRIOBP-5 variant failed to homo-oligomerize (Figure 7, B and D), consistent with the computational structural model showing that the coiled-coil domains permit homo-oligomerization (Figure 7 and Supplemental Figure 8).
TRIOBP-5 homodimerization revealed by nanoscale pull-down assays. (A) MYO10-HMM-Nanotrap (abbreviated MYO10NANOTRAP) specifically binds GFP derivatives, but not DsRed, and traffics GFP-tagged protein to filopodia tips. Representative image of a HeLa cell transfected with 3 expression vectors encoding MYO10NANOTRAP, AcGFP1-TRIOBP-5, and DsRed-TRIOBP-5 (upper panel), and a control HeLa cell transfected with the MYO10NANOTRAP, AcGFP1 vector, and DsRed-TRIOBP-5 (lower panel). AcGFP1-TRIOBP-5 and DsRed-TRIOBP-5 colocalize to filopodia tips (upper panel), while in the control, only the AcGFP1 vector localized at filopodia tips (lower panel). The complex of MYO10NANOTRAP and AcGFP1-TRIOBP-5 partnered with and transported DsRed-TRIOBP-5 to filopodia tips. The complex of MYO10NANOTRAP and AcGFP1 vector did not traffic DsRed-TRIOBP-5. These data indicate that TRIOBP-5 can homomultimerize in vivo. The second column shows enlarged images of the white-outlined areas from the first column. The third and fourth columns are the individual green and red channels of merged images in the second column. (B) Transfected HeLa cell with MYO10NANOTRAP, AcGFP1-TRIOBP-5Δcc, and DsRed-TRIOBP-5Δcc (upper panel), and control HeLa cell transfected with MYO10NANOTRAP, AcGFP1 vector, and DsRed-TRIOBP-5Δcc (lower panel). Triobp-5Δcc is deleted for sequence encoding the coiled-coil domains and 78 bp of upstream sequence. DsRed-TRIOBP-5Δcc was not trafficked to filopodia tips by the MYO10NANOTRAP and AcGFP1-TRIOBP-5Δcc, indicating that TRIOBP-5Δcc does not multimerize. (C) Left panel: Quantification of AcGFP1-TRIOBP-5 or AcGFP1 vector binding to DsRed-TRIOBP-5. When MYO10NANOTRAP, AcGFP1-TRIOBP-5, and DsRed-TRIOBP-5 were coexpressed, 90% ± 4.4% of filopodia (3 independent experiments) showed a statistically significant correlation between green and red fluorescence at filopodia tips (2-tailed t test). Right panel: Fluorescence intensities of DsRed-TRIOBP-5 at filopodia tips. The presence of AcGFP1-TRIOBP-5 caused a significant increase of fluorescence intensity of DsRed-TRIOBP-5 at the filopodia tips (Mann-Whitney U test). (D) Interaction index of either AcGFP1-TRIOBP-5Δcc or AcGFP1 vector with DsRed-TRIOBP-5Δcc (left panel). AcGFP1-TRIOBP-5Δcc does not bind to DsRed-TRIOBP-5Δcc. Fluorescence intensities of DsRed-TRIOBP-5Δcc at filopodia tips (right panel). AcGFP1-TRIOBP-5Δcc does not increase the intensity of DsRed-TRIOBP-5Δcc at filopodia tips, indistinguishable from the AcGFP1 vector control experiment. Scale bars: 10 μm. Data are mean ± SD. ****P < 0.0001.
TRIOBP-5 deficiency causes decreased apical stiffness of supporting cells. TRIOBP-4 and TRIOBP-5 are also expressed in sensory epithelium supporting cells and are localized to filamentous structures within the obliquely ascending Deiters’ processes and apical plates of outer pillar cells (Figure 1B; Figure 2, A and B; and Figure 6B). In TriobpΔEx9-10/ΔEx9-10 mice, the TRIOBP-5 antibody signal is absent from supporting cells (Figure 6C). We tested the hypothesis that TRIOBP contributes to the stiffness of the sensory epithelium by investigating the mechanical properties of the reticular lamina using PeakForce Tapping–mode atomic force microscopy (PFT-AFM), which allows simultaneous visualization and measurements of stiffness by gently indenting from 50 nm to no more than 500 nm the surface of live organ of Corti explants. The elastic Young’s modulus (E) (43) of the epithelium was measured, and nanoscale stiffness maps of P5 organ of Corti (middle turn) of mutant TriobpΔEx9-10/ΔEx9-10 and normal-hearing heterozygous TriobpΔEx9-10/+ littermates were generated (Figure 8A). At apical surfaces of pillar and Deiters cells of TriobpΔEx9-10/ΔEx9-10 mice, local stiffness of the reticular lamina was reduced approximately 2-fold compared with heterozygotes (Figure 8B and Supplemental Table 1). Thus, alteration of these filamentous structures in supporting cells deficient for TRIOBP-5 (Figure 9A) reduced axial compliance of the organ of Corti reticular lamina, likely affecting hearing sensitivity (21, 44, 45).
TRIOBP-5 deficiency results in decreased supporting-cell stiffness and fragile hair cell stereocilia. (A) Topographic image (top) and stiffness map (bottom) of live organ of Corti explants (P5, cochlear middle turn) from TriobpΔEx9-10/+ heterozygotes (left) and TriobpΔEx9-10/ΔEx9-10 mutant littermates (right) visualized by atomic force microscopy using PeakForce Tapping mode (PFT-AFM). Transverse stiffness (E, elastic Young’s modulus) of the reticular lamina measured in regions of interest (ROIs) overlaying supporting cells (for example, white square in TriobpΔEx9-10/ΔEx9-10 stiffness image). Scale bars: 5 μm. (B) Box-and-whisker plots of E values on apical surfaces of inner pillar (IPC), outer pillar (OPC), and Deiters’ row 1 (DC1) and 2 (DC2) cells. Bars show mean ± SD Asterisks indicate statistical significance between Triobp-5+/ΔEx9-10 and Triobp-5ΔEx9-10/ΔEx9-10 cells. ***P < 0.001 (2-tailed t test with Welch’s correction). n indicates the number of cells. Data points represent individual supporting cells for TriobpΔEx9-10/+ mice (gray) and TriobpΔEx9-10/ΔEx9-10 mice (purple), 5 and 4 mice, respectively. (C) Deflections of stereocilia bundles by a fluid-jet in wild-type (top) and TriobpΔEx9-10/ΔEx9-10 live IHCs (bottom). Responses to maximal pressure steps of ±25 mmHg are shown. See also Supplemental Video 3. The puff pipette is visible at the bottom of the panels. (D) Average displacements of stereocilia bundles as a function of fluid-jet pressure in wild-type (gray open symbols) and TriobpΔEx9-10/ΔEx9-10 (black solid symbols) IHCs at P8. Alternating positive and negative stimuli presented in increasing order. Examples of bundle deflections are shown in inset. Number of cells (number of mice): wild-type, n = 44 (6); TriobpΔEx9-10/ΔEx9-10 n = 49 (6). Data are shown as mean ± SEM. Asterisks indicate statistical significance of differences between wild-type and TriobpΔEx9-10/ΔEx9-10 mice. **P < 0.01; ***P < 0.001 (t test of independent variables).
Illustration of TRIOBP-4 and TRIOBP-5 distribution in inner ear supporting cells and working model of stereocilia pathology in TRIOBP-5–deficient mice. (A) TRIOBP-4 and TRIOBP-5 are both present in Deiters’ (DC1, DC2, and DC3) and outer and inner pillar cells (OPC, IPC) of normal-hearing TriobpΔEx9-10/+ heterozygotes. Only TRIOBP-4 remains in the same cell types of deaf TriobpΔEx9-10/ΔEx9-10 mouse. (B) Schematic of wild-type stereocilia with normal rootlet architecture (left). TRIOBP-5–deficient stereocilia with abnormally thin rootlets in the cuticular plate (right) but abnormally thick rootlets in the F-actin core that extend aberrantly to tips of stereocilia (right). TRIOBP-5 (purple) and TRIOBP-4 (blue) wrap around rootlet F-actin (insets) and in wild-type are hypothesized to allow filaments to slide past one another during sound-induced stereocilia deflections. TRIOBP-5 recruits more F-actin to shape rootlets and generates thicker bundles due to oligomerization by its coiled-coil domains.
Pivotal flexibility of stereocilia is diminished in TRIOBP-5–deficient hair cells. The contribution of TRIOBP-5 to the pivotal flexibility and durability of stereocilia was investigated by deflecting stereocilia bundles of live IHCs using stimuli of increasing intensity from a calibrated fluid-jet (Figure 8C). In WT IHCs, hair bundle deflections depended almost linearly on the pressure of the fluid-jet (Figure 8D). Deflections of the TriobpΔEx9-10/ΔEx9-10 IHC bundles did not differ from WT at low stimuli intensities. However, at higher stimuli intensities, the extent of the deflection of TriobpΔEx9-10/ΔEx9-10 IHC bundles was significantly larger compared with WT (Figure 8D and Supplemental Video 3). This nonlinear pressure-deflection relationship of TriobpΔEx9-10/ΔEx9-10 stereocilia recapitulates the mechanical behavior of the IHC bundles in mice lacking both TRIOBP-4 and TRIOBP-5 (8). Interestingly, evidence for more fragile stereocilia of TriobpΔEx9-10/ΔEx9-10 mice could be found not only in direct fluid-jet experiments (Figure 8D) but also in the PFT-AFM stiffness map data (Figure 8A). When a PFT-AFM probe lands on the tips of WT stereocilia, it generates peaks in the stiffness map that “outline” the hair bundle (Figure 8A). Although it is hard to interpret the values of these peaks due to a complex mechanical interaction between the PFT-AMF probe and a stereocilium, they largely disappear in TriobpΔEx9-10/ΔEx9-10 mice (Figure 8A, bottom right), also indicating that a TRIOBP-5 deficiency affects the mechanical properties of stereocilia. Thus, 2 independent techniques revealed similar deficits in the mechanical properties of stereocilia bundles.
The inner ear sensory epithelium must endure unremitting, life-long sound vibrations. Stereocilia rootlets of hair cells are one of the essential structures that provide this resilience. The absence of stereocilia rootlets causes deafness due to the degeneration of mechanosensory hair cells. We show here that the development of fully functional, morphologically distinctive stereocilia rootlets requires the specific functions of TRIOBP-5. Although essential, TRIOBP-4 is not sufficient to develop and sustain mature rootlets. Using 2 newly generated deaf mouse models, we demonstrated that TRIOBP-4 facilitates the initial formation of rootlets by promoting elongation into thin, tight bundles of F-actin, while TRIOBP-5 is essential for widening, sculpting, and then maintaining the intricate rootlet architecture. This study also provides the first evidence to our knowledge for a molecular subdivision of stereocilia rootlets of mammalian hair cells despite their uniform appearance in electron micrographs (26). The upper half of the rootlet within the stereocilium consists of actin filaments bundled predominantly by TRIOBP-4, while F-actin in the lower half of rootlets within the cuticular plate is bundled by both TRIOBP-4 and TRIOBP-5 (Figure 9B).
Elimination of TRIOBP-5 results in hypertrophy of the upper half of the rootlet and a thin, fragile lower half, while loss of just the C-terminal coiled-coil domains of TRIOBP-5 leads to easily damaged, bent, or splayed rootlets that have normal lengths. The TRIOBP-5 variant lacking coiled-coils, which is presumably responsible for the fluorescent signal in rootlets of TriobpΔEx8/YHB226 mice, cannot fully compensate for the function of full-length TRIOBP-5. This shorter version of TRIOBP-5 includes a PH domain and flanking sequence that fosters the mature shape of rootlets, restrains expansion into the upper half of stereocilia, and recruits additional actin filaments to thicken the lower half, but is not sufficient to provide resilience to stereocilia rootlets.
Using live cell NanoSPD assays, we show that coiled-coil domains are essential for oligomerization of TRIOBP-5, which appears to be a mechanism for holding actin bundles together. We propose that oligomerized TRIOBP-5 embraces filaments, allowing them to slide past one another within the bundle, thus providing flexible durability of rootlets during life-long deflection of stereocilia (8, 18). We also speculate that oligomerized TRIOBP-5 interacts with and integrates rootlets into the actin meshwork of the cuticular plate (Figure 9B), a function not fulfilled by TRIOBP-4. However, TRIOBP-4 is diffusely distributed within the cuticular plate and could help to organize its actin meshwork (Figure 9B). Because almost the entire sequence of TRIOBP-1 is identical to the sequence of the C-terminal part of TRIOBP-5, we could not exclude hetero-oligomerization of TRIOBP-5 and TRIOBP-1. However, in mice deficient for TRIOBP-4 and TRIOBP-5, but expressing TRIOBP-1, rootlets do not develop (8). A conditional knockout of TRIOBP-1 limited to hair cells is necessary to determine if TRIOBP-1 has a role in rootlet development or maintenance. Open questions also include the mechanisms targeting TRIOBP-4 and TRIOBP-5 to different compartments within stereocilia rootlets. Nevertheless, our observations indicate that the functions of TRIOBP-5 in rootlets are distinct from those of TRIOBP-4 and likely depend on its C-terminal actin-binding sites, PH domain, coiled-coil domains, or a combination of these functional modules (Figure 1A).
TRIOBP-5 is also essential for stiffening the reticular lamina, the tightly connected apical surfaces of sensory and supporting cells in the organ of Corti (34). Expression of TRIOBP-5 in the apical poles of the ascending Deiters’ cell processes and in outer pillar cells near contacts with the cuticular plates of OHCs (Figure 1B and Figure 9A) contributes to mechanical stiffness and resilience of the auditory sensory epithelium. Using PFT-AFM, we observed that the absence of TRIOBP-5 in the organ of Corti resulted in a significant decrease in the local axial stiffness of the supporting cells within the reticular lamina. Thus, in addition to hair cell stereocilia rootlets, TRIOBP-5 provides mechanical resilience to Deiters’ and pillar supporting cells of the organ of Corti that are also crucial for normal sound transduction.
In humans, a premature translation termination mutation (p.Gly1672*) in the sequence unique to TRIOBP-5 or 2 polymorphic variants of TRIOBP associate with moderate, progressive hearing loss (7), a phenotype similar to the progressive loss of hearing in our TRIOBP-5–deficient mouse and human age-related hearing loss, a common disorder in older adults (3). Over a lifetime, amino acid substitutions of TRIOBP protein or regulatory changes of the TRIOBP gene might subtly alter rootlet structure or rigidity of the apical surface of supporting cells, gradually compromising the armamentaria that safeguard hair cells against damage from sound-induced mechanical forces. In summary, our integrated genetic, morphological, physiological, and biophysical studies have revealed what we believe are unique F-actin cytoskeletal localizations and mechanisms of action of TRIOBP-5 and TRIOBP-4 within the inner ear sensory and non–sensory cells that in concert are required for normal hearing. The mechanisms of F-actin bundle formation by TRIOBP-5 and TRIOBP-4 isoforms uncovered in our study of deafness may help reveal the pathophysiology of other TRIOBP-associated disorders (TRIOBPopathies) and facilitate development of therapies.
R26-EGFP-Triobp-4 reporter mice. The R26-EGFP-Triobp-4 reporter mouse (accession no. CDB0289K: http://www2.clst.riken.jp/arg/reporter_mice.html) was generated from R26-EGFP-Triobp-4 conditional reporter mice (loxP-flanked STOP sequence in front of EGFP-Triobp-4 cDNA, accession no. CDB0280K) and backcrossed for 8 generations. In this study, our EGFP-Triobp-4 reporter is expressed under the ubiquitous transcriptional machinery of the noncoding RNA of the ROSA26 locus (46).
TRIOBP-5–deficient (TriobpΔEx9-10/ΔEx9-10) mice. The hearing phenotype of a mouse deficient only for the TRIOBP-5 isoform is unknown. Therefore, we used 2 different genetic strategies to engineer 2 new mutant mouse models, each deficient only for TRIOBP-5 (Figure 1A), which were backcrossed for more than 10 generations. The first 8 exons of mouse Triobp comprise the entire Triobp-4 transcript and also contribute to the 5′ end of the much longer Triobp-5 transcript. The sequence of exons 13 through 25 are common to both Triobp-5 and Triobp-1 transcripts (Figure 1A), while exons 9 to 12 are exclusive to Triobp-5 transcripts (NM_001039156).
One TRIOBP-5–deficient mouse model was engineered by deleting exons 9 and 10 (TriobpΔEx9-10), using a reported methodology (47). An 8-kb 5′ arm and a 4-kb 3′ arm for construction of the targeting vector were obtained from clone RP23-414K1 (BACPAC Resources Center). Except for the first 7 bp of Triobp exon 9 (112 bp) and 1 base at the 3′ end of exon 10 (1021 bp), the remainder of the deleted sequences of these 2 exons was replaced with an nLacZ reporter cassette inserted in frame with the upstream protein sequence of TRIOBP. TT2 ES cells (48) were electroporated with the NotI-linearized targeting vector, and ES clones were screened for homologous recombination events. PCR-positive ES cell clones were then evaluated by genomic Southern blot analyses using specific probes (5′ probe: 5′-CTACCCAGTCAGGCTTTGTTTTGTGGC-3′ and 5′-GCCAATGTGAACTGCTTAACTC-3′; 3′ probe: 5′-CTTGGTTTTTAATGTTAGAACCAGATTGGC-3′ and 5′-CTAACCATCAGCTCATTTCTTTGAG-3′). Three independent ES cell clones (numbers 18, 20, and 23) were selected and used to produce chimeric mice. Germ-line transmission of the targeted allele was obtained from all 3 lines. Mice engineered with the deletion of exon 9 and 10 are designated TriobpΔEx9-10, while the JAX nomenclature committee has designated this allele as Triobptm1Sik (MGI:6189198) with an accession number at Riken of CDB0844K (http://www2.clst.riken.jp/arg/mutant%20mice%20list.html). These mice are available to the scientific community.
TriobpΔEx8/YHB226compound heterozygous TRIOBP-5–deficient mice. A second TRIOBP-5 functional null mutant mouse was produced by crossing a Triobp-4/5 homozygous mutant mouse (TriobpΔEx8/ΔEx8) with a heterozygous Triobp-1/5 (TriobpYHB226/+) mouse (Figure 1C). Individually, both of these alleles were reported previously (8). TriobpΔEx8/YHB226 compound heterozygous mice were born at the expected Mendelian ratio and were indistinguishable by weight and growth rate (data not shown) from their normal hearing heterozygous (TriobpΔEx8/+) littermates. The contribution of TRIOBP-1 to stereocilia rootlet function, if any, awaits the development of a conditional knockout of TRIOBP-1 expression in hair cells, as a whole-body loss of TRIOBP-1 is lethal (8).
Genotyping and RT-PCR analysis. For TriobpΔEx9-10/ΔEx9-10 mice, genotyping was performed with the following primers in a single PCR reaction: primer-P1 (WT.F), 5′-CCAAGGCTTCAGGACCAGAG-3′; primer-P2 (mut.F), 5′-CCTTCTATCGCCTTCTTGACGAG-3′; primer-P3 (rev), 5′-CACACTGCTTGTCAGCTGGT-3′. The product size of amplimers using primers P1/P3 (WT) and P2/P3 (KO) are 399 bp and 276 bp, respectively. PCR conditions involved denaturation at 94°C for 2 minutes, 94°C for 30 seconds, 58°C for 30 seconds, and 68°C for 30 seconds, which was repeated for 35 cycles with a final extension at 68°C for 10 minutes. For R26-EGFP-Triobp-4 reporter mice, all primers were used in a single PCR reaction: primer-P1 (forward), 5′-TCCCTCGTGATCTGCAACTCCAGTC-3′; primer-P2 (WT.R), 5′-AACCCCAGATGACTACCTATCCTCC-3′; and primer-P3 (LoxP.R), 5′-GCTGCAGGTCGAGGGACC-3′; the product size of amplimers using primers P1/P2 and P1/P3 are 217 bp and 270 bp, respectively. PCR reaction conditions involved a denaturation step at 96°C for 2 minutes, then 96°C for 30 seconds, 65°C for 30 seconds, and 72°C for 30 seconds, which was repeated 35 times, and a final extension at 72°C for 10 minutes.
TriobpΔEx8/YHB226 compound heterozygous mice were genotyped using primers Tara Ex8.F3, 5′-CAGGCAACAATGTCTTGGCG-3′; Tara Ex8.WTR3, 5′-TGGGTAACGCCAGGGTTTTC-3′; and Tara Ex8.KOR1, 5′-GGTTCTGTTGAGAGAGGAGTCTTGG-3′ as described previously (8), where the product sizes are 645 bp for WT and 338 bp for the mutant allele. The TriobpYHB226 allele was genotyped using 3 primers in 1 tube: YHB226.F1, 5′-AGGCTCTCCGACTGCAATAA-3′; YHB226.En2ExRv, 5′-ATGCGATCTGCGTTCTTCTT-3′; and YHB226.WTR3, 5′-GCTTTTCCAACTCCTGCCACTTC-3′. The product size of the amplimer for WT is 424 bp and 726 bp for the mutant allele, using the same thermocycler conditions described previously (8). Briefly, after denaturation at 94°C for 2 minutes, there was 35 cycles of 94°C for 30 seconds, 55°C for 30 seconds, and 68°C for 1 minute and a final extension at 68°C for 10 minutes.
Internally deleted Triobp-5 transcripts were amplified from P3 WT cochlear cDNA using primers 5′-TTCCAGACTCGGGATGAGGGAC-3′ and 5′-CCCCTGTATCCCATTACTG-3′ (8). Expression of this transcript in TriobpΔEx8/YHB226 deaf heterozygotes was confirmed using a forward PCR primer that was complementary to the sequence at the junction of exons 14 and 15 (5′-CTTCCAGATCCACACCAAGGAC-3′) and a reverse primer 5′-CCTGAAGAAGGTGCAAGGTAAAGAC-3′ complementary to the sequence in exon 24. The products were verified by Sanger sequencing.
ABR and DPOAE measurements. In each mouse, cochlear hearing function was tested by ABR and DPOAE at 4, 8, and 12 weeks of age inside a sound-proof booth (Acoustic Systems), while resting on a heating pad connected to a temperature controller and rectal probe (World Precision Instruments) to maintain body temperature near 37°C. Mice were anesthetized via an intraperitoneal injection of a solution of ketamine (56 mg/kg) and Dexdomitor (Pfizer) (0.375 mg/kg). DPOAEs and ABRs were measured using Tucker-Davis Technologies (TDT) hardware (RZ6 Multi I/O processor, MF-1 speakers) and software (BioSigRz, v. 5.7 or 5.7.1). DPOAEs were recorded first using 2 TDT MF-1 speakers and an ER-10B+ microphone (Etymotic) coupled to the mouse’s ear using a modified pipette tip. A 10-μl pipette tip was trimmed to achieve 10 mm in length and 2 mm in the diameter at the tip opening. DPOAE (2f1 – f2) levels were obtained in response to 2 primary tones at f1 = 65 dB sound pressure level (SPL) and f2 = 55 dB SPL, with f2 varied from 4 to 44.8 kHz (5 points/octave) and f2/f1 = 1.25. The mean noise floor was calculated from 3 points sampled above and 3 points sampled below the 2f1 – f2 frequency. DPOAE signals were converted to dB SPL according to the calibration of an ER-10B+ microphone provided by the manufacturer. ABR thresholds were determined by presenting Blackman-gated tone-burst stimuli (3 ms duration, 29.9/s, alternating polarity) at 8, 16, and 32 kHz. Subdermal needle electrodes were placed at the cranial vertex and beneath each pinna, with the non–test ear serving as the ground. Stimuli were delivered via a TDT MF-1 speaker in a closed-field configuration. PVC tubing provided with the speaker was terminated in a modified pipette tip of the same dimensions as the one used with the DPOAE microphone. Responses were amplified (20×), filtered (0.3–3 kHz), and digitized at 25 kHz. Thresholds were determined through visual inspection of stacked waveforms (average of 512–1024 artifact-free responses per waveform). The stimulus was presented first at 80 dB SPL and then decreased in 10- to 20-dB steps until the ABR waveform disappeared. The stimulus was then increased and decreased in 5-dB steps until the lowest stimulus level that produced a repeatable waveform (ABR threshold) was determined. At least 2 waveforms (1,024 responses each) were obtained for stimulus levels at and near the ABR threshold to ensure repeatability of the response. If no response was evident at 80 dB SPL, the stimulus level was increased to 90 dB SPL and testing proceeded as described above. When no repeatable waves were visible at the highest stimulus level tested (90 dB SPL), the threshold was designated as 100 dB SPL for subsequent analyses.
β-Gal staining. Inner ears dissected from P13 TriobpΔEx9-10/+ heterozygous mice were fixed with 0.2% weight per volume (w/v) glutaraldehyde and 2% (w/v) paraformaldehyde (PFA) in PBS for 20 minutes at room temperature. The cochlear bone was removed in 2 mM MgCl2, 0.01% sodium deoxycholate, and 0.02% Nonidet P-40 in phosphate buffer (pH 7.3), and then stained with 2 mg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-Gal), 15 mM potassium ferricyanide, 15 mM potassium ferrocyanide, 2 mM MgCl2, 0.01% sodium deoxycholate, and 0.02% Nonidet P-40 in phosphate buffer (pH 7.3). After staining, samples were postfixed with 4% (w/v) PFA in PBS at 4°C for 6 hours, incubated in 15% sucrose in PBS at 4°C overnight, mounted in OCT, and frozen in liquid nitrogen. Frozen sections were cut at 8-μm thickness. WT P13 mouse cochleae were processed simultaneously to serve as a control. No β-Gal signal was observed in control inner ear tissues.
Gene gun–mediated transfection. Organ of Corti sensory epithelia were dissected from P0–P3 C57BL/6J WT mice and cultured overnight in DMEM/F12 medium supplemented with 7% FBS at 37°C and 5% CO2. Epithelial explants were then transfected with AcGFP1-Triobp-4 and AcGFP1-Triobp-5 using 1-μm gold carriers coated with cDNA and delivered via gene gun–mediated transfection using helium at 110 psi as described previously (36, 49). After 24 hours of transfection, sensory epithelial explants were washed 2 times in 1× PBS and fixed in 4% PFA for 2 hours at room temperature or overnight at 4°C, permeabilized in 0.1% Triton X-100, and counterstained with Rhodamine-phalloidin or Alexa Fluor 546–phalloidin at 1:100 dilution in 1× PBS for 15–20 minutes at room temperature following 3 washes of 10 minutes each in 1× PBS. Transfected and counterstained sensory epithelial explants were removed from the culture dish using a fine needle and mounted on a glass slide with Prolong Antifade (Thermo Fisher Scientific). The images were obtained using a Zeiss LSM780 confocal microscope equipped with a 63×, 1.4 N.A. objective (Zeiss).
Antibodies. The custom rabbit polyclonal antibodies against TRIOBP isoforms 4/5 and TRIOBP 5 were prepared and used as described previously (8). Mouse monoclonal anti-GFP antibody was obtained from Fujifilm Wako Pure Chemical Corporation (catalog 012-20461), and Alexa Fluor 488 goat anti-rabbit IgG pAb (catalog A11008), Alexa Fluor 546 goat anti-rat IgG pAb (catalog A11081), and Alexa Fluor 546-phalloidin (catalog A22283) were obtained from Thermo Fisher Scientific.
Immunofluorescence microscopy. The inner ears from mice at P5, P12, and P32 were dissected and fixed for 20 minutes with 2% (w/v) formaldehyde in PBS at room temperature. Tissues were washed with 1× PBS, microdissected and permeabilized in 0.2% (w/v) Triton X-100 for 15 minutes at room temperature. The samples were blocked with 2% bovine serum albumin (BSA) and 5% normal goat serum in PBS and incubated with primary antibodies at 5 μg/ml followed by Alexa Fluor–conjugated secondary antibodies at 2–5 μg/ml. Samples were washed in 1× PBS 3 times, 10 minutes each, and mounted using ProLong Gold antifade reagent (Thermo Fisher Scientific) and imaged with an LSM780 and a 63× 1.4 NA objective. Some samples were mounted in Fluoromount-G (SouthernBiotech) and imaged with an SP8 confocal microscope (Leica Microsystems).
SEM. Inner ear tissue from mice at P7, P14, P30, and P40 was processed as described previously (50) or briefly fixed in 2% (w/v) PFA in PBS followed by 2.5% glutaraldehyde in 100 mM HEPES buffer for 2 hours. After fixation, the bony capsule was decalcified with 5% (w/v) EDTA for 24 hours in PBS, the organ of Corti was microdissected and dehydrated with a dilution series of ethanol (50%, 60%, 70%, 80%, 90%, 99%, and 100%), immersed in t-butanol, frozen at –20°C, and the t-butanol sublimated off. Samples were then sputter-coated with platinum-palladium alloy using an ion coater (IB-3; Eiko) and observed by SEM (S-4700 and S-4800, Hitachi).
TEM and serial section TEM. Cochleae were fixed in 2% PFA and 2.5% glutaraldehyde in HEPES, dehydrated in a series of ethanol dilutions (65%, 75%, 85%, 95%, 99%, and 100%) followed by 100% propylene oxide and embedded in Epon 812. Ultrathin sections of 70-nm thickness were cut with a diamond knife and stained with uranyl acetate and/or lead citrate. Samples were observed by TEM (H-7650 and 1200, Hitachi or JEM-2100, JEOL).
For serial section TEM, whole P16 cochleae from WT and TRIOBP-mutant mice were thin-sectioned on a Leica Ultramicrotome at 60 nm. Serial sections were placed on single-slot grids with a carbon/formvar film (EMS) and stained with lead citrate. Several series of sections ranging from 7–12 sections were examined in a JEM-2100 TEM (JEOL). For each section, the apex of the inner and outer hair cells from basal, middle, and apical turns were photographed at low, middle, and high magnification (total of 1,813 TEM micrographs). Subsequently, these images were rotated in Adobe Photoshop to adjust their orientation and processed using 3D-reconstruction software (Reconstruct, copyright 1996–2007 by John C. Fiala; funded by the Human Brain Project and NIH) (51).
FIB-SEM tomography. FIB-SEM samples were prepared by a modified Ellisman method (52). Samples were dissected as for TEM, and incubated with 1.5% potassium ferrocyanide followed by 2% osmium tetroxide in deionized water (DW) at 4˚C. After 1 hour, the tissues were washed with distilled water (DW) and fixed with 2% osmium tetroxide in DW at room temperature for 1 hour. The fixed cochleae were dehydrated with a dilution series of ethanol (65%, 75%, 85%, 95%, 99%, and 100%) and propylene oxide and were embedded in Epon 812.
The specimens were set on the stage of a FIB-SEM (Quanta 3D FEG, FEI or CrossBeam 540, Zeiss). Microfabrication around the reconstruction area was performed as previously described (53). Approximately 1,000 block-face serial images were acquired by repeated cycles of sample surface milling and imaging using Slice and View G2 software (FEI) and smartFIB (ZEISS), respectively. The milling was performed with a gallium ion beam at 30 kV with a current of 2 or 7 nA. The milling pitch was set at 20 nm/step. The images were acquired at a landing energy of 2.5 keV with a stage bias voltage of 3 kV (Quanta FEI) or 1.5 keV (CrossBeam Zeiss). The other acquisition parameters were as follows: beam current = 50 pA or 1 nA, dwell time = 4 μs/pixel, image size = 2048 × 1766 pixels (10.0 μm × 10.9 μm), pixel size = 4.86 nm × 6.17 nm/pixel; scan speed = 2.8 min/image, image size = 4096 × 3072 pixels (40.96 μm x 30.72 μm), pixel size = 10 nm × 10 nm/pixel. The resultant image stacks were processed using Dragonfly 3.1 software (ORS Inc.) and Avizo 6.3 software (FEI).
Nanoscale pull-down (NanoSPD) protein-protein interaction assay. The possibility that TRIOBP-5 homomultimerizes was experimentally tested using NanoSPD 2.0 assays (42) and observations were evaluated using spatial correlation and intensity correlation analyses. A NanoSPD assay is an in vivo affinity pull down that harnesses the ability of the myosin-10 motor domain (heavy meromyosin, HMM) to move on F-actin to the tips of filopodia. Myosin-10 HMM was fused to the sequence of a GFP-Nanotrap (single-domain antibody) on the carboxy terminus of a myosin-10 HMM. The MYO10-HMM-nanotrap (Addgene, pcDNA3.1-MYO10-HMM-Nanotrap, 87255, abbreviated MYO10NANOTRAP) binds to and transports a GFP-tagged protein bait of interest to filopodia tips. Here, TRIOBP-5 as bait was epitope tagged with GFP, and when coexpressed in HeLa cells (ATCC, CCL-2) is transported to filopodia tips. At the same time, if HeLa cells are also transfected with DsRed-TRIOBP-5 as prey, and if TRIOBP-5 can homomultimerize, it is also transported to filopodia tips by the AcGFP1-TRIOBP-5 bound to the Nanotrap (42). The readout is yellow fluorescence at filopodia tips, indicating that an interaction between TRIOBP-5 molecules has occurred. Controls are shown in Figure 7 and Supplemental Figure 9). The Triobp-5Δcc expression vector in which the coiled-coil domains were deleted was constructed using 3 fragments from the full-length Triobp-5 cDNA that were combined using In-Fusion cloning (Takara, 638912), such that sequences encoded by exons 11, 12, and 15–22 were deleted. For transfection into HeLa cells in 6-well dishes, we used expression vectors (equal molar amounts for a total of 2.0 μg of DNA) that separately express AcGFP1-TRIOBP-5, DsRed-TRIOBP-5, and the MYO10NANOTRAP per well. HeLa cell transfections were performed using Lipofectamine 3000 (Thermo Fisher Scientific, L3000008).
PFT-AFM imaging. Freshly dissected P5 organ of Corti sensory epithelium from TriobpΔEx9-10/ΔEx9-10 mutant and TriobpΔEx9-10/+ heterozygous littermates was plated on a glass-bottom dish (HBST-5040, Willco Wells) precoated with 10 μl of Cell-Tak (Corning) and immersed in Leibovitz media (L-15, 21083-027, Life Technologies). Blinded to the genotype, PFT-AFM experiments were performed on a Bruker Bioscope Catalyst AFM system (Bruker) directly mounted on an inverted Axiovert 200M microscope (Zeiss) equipped with a confocal laser scanning microscope (510 Meta, Zeiss) and a 40× objective lens (0.95 NA, Plan-Apochromat, Zeiss). During experiments, explants were maintained at 37°C using a Bruker heated stage. An AFM probe specially designed for live cell imaging (PFQNM-LC, Bruker) has a tip height of 17 μm, controlled tip radius of 65 nm, and opening angle of 15°. The cantilevers (Bruker, PFQNM-LC-A-CAL) were precalibrated by the Bruker system using a laser Doppler vibrometer. The spring constant range of the cantilever was 0.06–0.08 N/m. For PFT-AFM imaging, we used a driving frequency of 500 Hz and drive amplitudes of 500 nm to 650 nm. The scan speed used was 0.5 Hz. The PeakForce feedback was set between 800 pN and 1.2 nN. The scan resolution of all images was 256 × 256 pixels. The elastic Young’s modulus (stiffness) calculations were performed using NanoScope Analysis software (Bruker). The elastic Young’s modulus is a mechanical property that describes the stiffness of a material. It relates the stress against the strain of a material in the linear elastic region (43). The elastic Young’s modulus (E; Pa) was computed by fitting each force-distance curve with the Sneddon’s contact mechanics model for indenting an infinite isotropic elastic half-space with a conical indenter:
FSneddon = (8Etanα/3 π)δ2, where F is the applied force, α is the tip half-opening angle, and δ is the sample mean indentation.
Pivotal flexibility of hair cell stereocilia. Flexibility of the IHC bundles was estimated in acutely isolated mouse organ of Corti explants. The explants were dissected at P8 in L-15 cell medium and mounted in glass-bottom Petri dishes with a pair of dental floss monofilaments. IHC bundles were observed at room temperature with an upright microscope (E600FN, Nikon) equipped with a 60× water-immersion objective (1.0 NA, 2.0 mm working distance) and a 1.6× secondary magnification lens. IHC stereocilia bundles were deflected with a fluid-jet as described previously (8). Briefly, a micropipette of an approximately 6 μm inner diameter and filled with bath solution (L-15, Invitrogen) was positioned at a distance of approximately 6 μm in front of the hair bundle and pressure steps were generated by a High-Speed Pressure Clamp (HSPC-1, ALA Scientific) applied to the back of this pipette. According to our calibrations, the force generated by this microjet depends linearly on the applied pressure (Supplemental Figure 8 in ref. 8). The same pipette was used to deflect stereocilia bundles of WT and TriobpΔEx9-10/ΔEx9-10 mice. The steady-state pressure was adjusted to zero by monitoring debris movement in front of a fluid-jet.
Movements of stereocilia were video recorded with a CMOS camera (Flea3, PointGrey; FLIR Integrated Imaging Solutions) for subsequent frame-by-frame computation of displacements using algorithms developed for quantifying electromotility of isolated OHCs. Briefly, the intensity profiles across a middle of the bundle were collected for each frame of the video record. The numbers of points in these profiles were interpolated 50 times to obtain subpixel resolution. The frame-by-frame shifts of the intensity profiles, and hence bundle position, were determined by the least-squares algorithm. The typical error of the movement measurements with this technique is approximately 20 nm (54). Then, the slow drift of the bundle position, if present, was corrected, deflections of the bundle were automatically detected, and their amplitudes were measured with the drift correction and automated event detection features of the pClamp 10 software (Molecular Devices) that was developed for the analysis of single-channel activity in patch-clamp recordings.
Statistics. All experiments were repeated at least 3 times. Data are shown as mean ± SEM or mean ± SD as indicated in figure legends. Student’s t tests of independent variables (2-tailed distribution) or Mann-Whitney U tests were used to determine statistical significance and a P value less than 0.05 was considered significant.
Study approval. The use of mice was approved by the Animal Research Committee of Kyoto University Graduate School of Medicine (permit number 11179), the Animal Care and Use Committees at the NIH (protocol 1263 to TBF), the University of Kentucky Animal Care and Use Committee (protocol 903M2005 to GIF), and the Institutional Animal Care and Use Committee of RIKEN Kobe Branch (permit number A2001-03-68) and conducted according to the NIH Guide for Care and Use of Laboratory Animals (National Academies Press, 2011).
TK, IAB, TBF, and SK conceived the project and experiments. TK, IAB, AXCR, K. Ohta, SMC, RSP, K. Ono RT, AI, AR, HK, MK, YXW, TA, MI, CFF, GPR, EAW, TSF, KS, K. Omori, and JI conducted experiments. TK, IAB, GIF, TBF, and SK wrote the manuscript and all authors edited the manuscript.
This work was supported in part by NIH National Institute on Deafness and Other Communication Disorders (NIDCD) Intramural Research Programs (DC000039-20 to TBF, DC000080 to TSF, ZICDC000081 to RSP and Y-XW, and 1ZIADC00003322 to Richard Chadwick, who supports AXCR); by the Intramural Research Program of the National Institute of Mental Health/NIH (ZIAMH002946) who in part supports CFF; NIDCD/NIH (R01DC014658 to GIF), JSPS KAKENHI grant 26293369 and 17H04345 to SK; and JP16H06280 to K. Ota. We thank Joseph A. Duda, Barbara Zwiesler, Alec Callahan, Patrick Diers, Jim McGehee, and animal facility staff at NIDCD/NIH; and Benjamin Perrin and Douglas Epstein for critically reading the manuscript. We thank H. Kohda and K. Okamoto-Furuta for assistance with EM image acquisitions and Y. Kimura and Richard Chadwick for helpful discussions.
Address correspondence to: Thomas B. Friedman, National Institute on Deafness and Other Communication Disorders, NIH, 1F-141 Porter Neuroscience Center, 35 Convent Drive, Bethesda, Maryland 20892, USA. Phone 301.496.7882; Email: friedman@nidcd.nih.gov. Or to: Shin-ichiro Kitajiri, Department of Otorhinolaryngology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan. Phone: 81.263.37.2666; Email: kitajiri@shinshu-u.ac.jp.
K. Ono’s present address is: Laboratory of Molecular Biology, NIDCD, NIH, Bethesda, Maryland, USA.
AR’s present address is: New York Genome Center, New York, New York, USA.
Conflict of interest: The authors have declared that no conflict of interest exists.
Copyright: © 2019, American Society for Clinical Investigation.
Reference information: JCI Insight. 2019;4(12):e128561. https://doi.org/10.1172/jci.insight.128561.